Skip to main content
Entero Therapeutics, Inc. logo

Entero Therapeutics, Inc. — Investor Relations & Filings

Ticker · ENTO ISIN · US33749P1012 US Manufacturing
Open in API
Filings indexed 724 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country US United States of America
Listing US ENTO

About Entero Therapeutics, Inc.

https://enterothera.com/

Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic, and orally delivered therapies for gastrointestinal (GI) diseases. The company's portfolio is centered on three proprietary technologies: latiglutenase, a first-in-class oral biotherapeutic designed to degrade gluten for patients with celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for GI indications such as gastroparesis; and adrulipase, a recombinant lipase enzyme to aid fat digestion in patients with exocrine pancreatic insufficiency resulting from cystic fibrosis or chronic pancreatitis. Entero's pipeline addresses a range of digestive disorders and autoimmune-related GI conditions.

Recent filings

Filing Released Lang Actions
FORM S-1
Regulatory Filings Classification · 89% confidence The document is a Form S-1 Registration Statement (preliminary prospectus) filed under the Securities Act of 1933. It is not an annual or interim financial report, nor a notice of dividend, board change, or earnings release. It is a regulatory compliance filing for the registration of securities, which falls under the general “Regulatory Filings” category as there is no specific code for SEC registration statements like Form S-1.
2026-05-27 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-27 English
FORM 8-K
Capital/Financing Update Classification · 87% confidence The document is a Form 8-K Current Report filed under the Securities Exchange Act of 1934. It discloses entry into a Material Definitive Agreement (Item 1.01), specifically a Debt Settlement and Subscription Agreement involving cash payment and issuance of common stock to settle a revolving loan. This constitutes a financing activity and change to the company’s capital structure. Therefore, it fits the Capital/Financing Update category.
2026-05-20 English
10-K - GridAI Technologies Corp. (0001604191) (Filer)
Annual Report FY 2025
2026-05-01 English
8-K - GridAI Technologies Corp. (0001604191) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports a triggering event related to a financial obligation default under a Revolving Loan Agreement, including details about the default, demand for payment, and ongoing discussions with the lender. The document does not contain comprehensive financial statements or detailed financial analysis but rather an update on a specific material event affecting the company. This fits the definition of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 4658 characters, which is consistent with a typical 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-04-24 English
8-K/A - GridAI Technologies Corp. (0001604191) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It amends a previously filed Form 8-K to include additional information such as risk factors, business overview, audited financial statements of an acquired company, and unaudited pro forma financial information. The document is not a full annual or quarterly report but an amendment to a current report disclosing a significant corporate event (a share exchange agreement and acquisition). Form 8-K filings and their amendments are classified as Regulatory Filings (RNS) because they are general regulatory announcements and do not constitute full financial reports like 10-K or 10-Q. The document length (5879 characters) and content confirm it is a regulatory filing rather than a full report or presentation.
2026-04-13 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.